Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy.

Roberto Caporali, Fabrizio Conti, Stefano Alivernini, Fabiola Atzeni, Bruno Seriolo, Maurizio Cutolo, Guido Valesini, Gianfranco Ferraccioli, Piercarlo Sarzi-Puttini, Carlo Salvarani, Serena Guiducci, Giuseppe Zampogna, Elisa Gremese, Nicolo' Pipitone, Rossana Scrivo, Serena Bugatti, Carlomaurizio Montecucco, Marco Matucci-Cerinic, Society for Rheumatology Italian Society for Rheumatology

Research output: Contribution to journalArticle

Abstract

Given the availability of novel biologic agents for the treatment of rheumatoid arthritis (RA), various national scientific societies have developed specific recommendations in order to assist rheumatologists in prescribing these drugs. The Italian Society for Rheumatology (Società Italiana di Reumatologia, SIR) decided to update its recommendations and, to this end, a systematic literature review was carried out and the evidence derived from it was discussed and summarised as expert opinions. Levels of evidence, strength of recommendations and levels of agreement were reported. The recommendations reported are intended to help prescribing rheumatologists to optimise the use of biologic agents in patients with RA seen in everyday practice; they are not to be considered as a regulatory rule.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume29
Issue number3 Suppl 66
Publication statusPublished - May 2011

    Fingerprint

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Caporali, R., Conti, F., Alivernini, S., Atzeni, F., Seriolo, B., Cutolo, M., Valesini, G., Ferraccioli, G., Sarzi-Puttini, P., Salvarani, C., Guiducci, S., Zampogna, G., Gremese, E., Pipitone, N., Scrivo, R., Bugatti, S., Montecucco, C., Matucci-Cerinic, M., & Italian Society for Rheumatology, S. F. R. (2011). Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clinical and Experimental Rheumatology, 29(3 Suppl 66).